Deep Brain Stimulation in HUCH Region Between 2006 and 2014
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02652104|
Recruitment Status : Completed
First Posted : January 11, 2016
Last Update Posted : January 11, 2016
|Condition or disease|
Deep brain stimulation is a FDA approved method in treating patients with advanced Parkinson's disease when the best medical treatment is insufficient. In this study the aim is to investigate the outcome of deep brain stimulation treated patients in Helsinki and Uusimaa University hospital between 2006 and 2014. This study is a retrospective study based on existing patients' medical records and does not include an intervention in the treatment of an individual patient.
Deep brain stimulation carries the risks of major surgery. A complication risk for a hemorrhage is 1-2 % and for an infection is 3-10%. The aim of this study is to evaluate the complications that have occurred and the possible benefit of deep brain stimulation in deep brain stimulation treated patients with advanced Parkinson's disease.
The gathered data will be processed anonymously and an individual patient cannot be identified. The data will be processed with an appropriate statistical program (SPSS). No data will be given to external parties.
|Study Type :||Observational [Patient Registry]|
|Actual Enrollment :||140 participants|
|Target Follow-Up Duration:||2 Years|
|Official Title:||A Review of the Clinical Outcome of Deep Brain Stimulation in the Patients With Advanced Parkinson's Disease in Helsinki and Uusimaa Hospital Between 2006 to 2014|
|Study Start Date :||January 2006|
|Actual Primary Completion Date :||December 2014|
|Actual Study Completion Date :||July 2015|
- The benefit of deep brain stimulation in the well-being (measured in UPDRS III, H&Y scale) of a patient with advanced Parkinson's disease [ Time Frame: at six months post-DBS ]
- The possible complications of deep brain stimulation in patient with advanced Parkinson's disease [ Time Frame: years ]
- The possible decrease in dosage of anti-Parkinsonian drugs after deep brain stimulation [ Time Frame: years ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02652104
|Study Director:||Eero Pekkonen, M.D.,Ph.D.||Chief Physician|